Clinical trials: Pyoderma Gangrenosum
Pyoderma Gangrenosum
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
- Trial name
- NCT03137160
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Pyoderma Gangrenosum, Hidradenitis Suppurativa
JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
The investigators hypothese that Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway play a key role in pathophysiology of pyoderma gangrenosum (PG).
- Conditions
- Pyoderma Gangrenosum, Hidradenitis Suppurativa, Psoriasis
- Trial name
- NCT04792957
- Testing
- immunohistochemical methods
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Dokuz Eylul University